Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.55 |
| ▸ | NPY1R | P25929 | 7/20 | 0.55 |
| ▸ | NPY2R | P49146 | 5/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30998029 | 1.00 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL30464872 | 0.94 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL9419225 | 0.94 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL9419221 | 0.94 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL31074747 | 0.94 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL29419494 | 0.92 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL13449160 | 0.91 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29419547 | 0.90 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29797028 | 0.90 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL3933285 | 0.89 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129118-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | H LEE MOFFITT CANCER CT & RES (US) | 2025-04-24 | — | — | US | claimed |
| US-20250129118-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | H LEE MOFFITT CANCER CT & RES (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2024153981-A1 | A MEDICINAL PRODUCT FOR USE IN ADMINISTERING IN THE TREATMENT, CONTROL AND/OR PREVENTION OF PAIN | PVP LABS PTE. LTD. (SG) | 2024-07-25 | — | — | WO | disclosed |
| EP-4355376-A1 | METHODS AND MATERIALS FOR COMBINING BIOLOGICS WITH MULTIPLE CHELATORS | Mayo Foundation for Medical Education and Research (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20230190857-A1 | PEPTIDE WITH AMIDATED CARBOXY TERMINUS HAVING MELANOGENESIS INHIBITORY ACTIVITY AND COMPOSITION COMPRISING SAME | RUBY CROWN CO. LTD. (KR) | 2023-06-22 | — | — | US | disclosed |
| WO-2022266499-A1 | METHODS AND MATERIALS FOR COMBINING BIOLOGICS WITH MULTIPLE CHELATORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129118-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | MC1R, MC3R, MC5R | NPY4R 40/4885NPY1R 14/4885NPY2R 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.